Form 4: GeneDx Holdings CFO Kevin Feeley Reports Routine Stock Transactions Following RSU Vesting

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, reported the acquisition of shares from restricted stock unit vesting and a subsequent 'sell to cover' transaction to satisfy tax obligations.

Summary

• Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), reported transactions on June 9, 2025.
• He acquired 2,462 shares of Class A Common Stock through the vesting and settlement of Restricted Stock Units (RSUs) at a price of $0 per share.
• Concurrently, he disposed of 1,266 shares of Class A Common Stock at a price of $72.55 per share.
• This sale was explicitly stated to cover tax withholding obligations related to the RSU vesting and was not a discretionary transaction.
• Following these transactions, Mr. Feeley beneficially owns 5,301 shares of Class A Common Stock directly and 14,773 Restricted Stock Units.
• The RSUs vest in quarterly installments of 6.25% over a four-year period, commencing March 9, 2023, contingent on his continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's a sale of shares, it's explicitly for tax purposes (sell to cover) and not a discretionary sale, which is a common and expected event for RSU vesting. The vesting itself is a positive for the executive and indicates continued compensation.

Positives

• The vesting of 2,462 Restricted Stock Units (RSUs) represents a non-cash compensation benefit to the Chief Financial Officer.
• The transaction indicates the continued retention and compensation of a key executive.

Negatives

• The sale of 1,266 shares, although for tax purposes, reduces the direct equity ownership of the Chief Financial Officer in the company.

Future Outlook

NA

Management Comments

• "The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs."
• "The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person."

Industry Context

This Form 4 filing is a routine disclosure of an executive's equity compensation transaction, common across all publicly traded companies, particularly those that utilize Restricted Stock Units (RSUs) as part of their executive incentive programs. It does not provide specific insights into broader industry trends for the biotechnology or genomics sector.

Stakeholder Impact

• Shareholders: The sale of shares by the CFO, even for tax purposes, slightly increases the float, but the impact is minimal given the small number of shares relative to the total outstanding. It does not signal a lack of confidence.
• Employees: The RSU vesting demonstrates the company's commitment to equity-based compensation for its executives, which can be a positive signal for other employees with similar compensation structures.

Next Steps

• Continued vesting of the remaining 14,773 Restricted Stock Units (RSUs) in quarterly installments over the 4-year period commencing March 9, 2023, subject to the CFO's continued service.

Key Dates

Recommendation

Keywords

GeneDx Holdings Corp., WGS, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Sell to Cover, Executive Compensation, Kevin Feeley, Chief Financial Officer, Stock Transaction